

Press Release



ASKA Pharmaceutical Terminates Option Agreement with KinoPharma regarding Cervical Dysplasia Treatment

TOKYO, April 7, 2023 - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter referred to as “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi, hereinafter referred to as “the Company”) announced that ASKA will terminate an option agreement with KinoPharma, Inc. (Headquarters: Chuo-ku, Tokyo/ CEO: Masafumi Kuroishi, hereinafter “KinoPharma”) regarding cervical dysplasia treatment.

The agreement was entered into on January 14, 2020 as an exclusive option agreement to obtain development and marketing rights in Japan for a cervical dysplasia treatment under development by KinoPharma. KinoPharma conducted a Ph I/II clinical trial in the Republic of Korea, however, ASKA has decided not to exercise its option right.

The impact of this matter on the Company's financial results for the fiscal year ending March 31, 2024 will be immaterial.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp